Next Questions: Acute Lymphoblastic Leukemia
By Bijal Shah, MD, MS - Last Updated: February 2, 2023At the 2021 Society of Hematologic Oncology Annual Meeting, Bijal Shah, MD, MS, of Moffitt Cancer Center, discussed what to expect going forward in the field of acute lymphoblastic leukemia.
Advertisement
Post Tags:SOHO21
Advertisement
Related Posts
Measurable residual disease has a prominent role in risk assessment, prognosis, and management decisions in T-ALL and B-ALL.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
CTD402 will be studied in a single-arm, open-label, phase 1b/2 trial with a simplified dose-finding design.
The approval is based on the E1910 trial, which compared blinatumomab and consolidation chemotherapy with chemotherapy alone.
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.